- Home
- TMQ vs PSNL Comparison
TMQ vs PSNL Comparison
Compare TMQ & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMQ | PSNL |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 700.5M | 729.1M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TMQ | PSNL |
|---|---|---|
| Price | $3.87 | $6.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | ★ 2.8M | 1.5M |
| Earning Date | 04-02-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.47 |
| Revenue Next Year | N/A | $39.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $3.09 |
| 52 Week High | $11.29 | $11.50 |
Technical Indicators
Market Signals| Indicator | TMQ | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 34.43 |
| Support Level | $3.79 | $4.65 |
| Resistance Level | $4.55 | $9.64 |
| Average True Range (ATR) | 0.24 | 0.50 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 60.27 | 8.06 |
Price Performance
Historical ComparisonAbout TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.